Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Schrodinger (SDGR) stock in plain English

Free brief · no signupStart here
SDGRPublished Nov 17, 2026
Schrodinger Inc
Healthcare · Health Information Services
Licenses physics-based software platforms to biopharmaceutical and industrial companies for molecular modeling.
Assets:
Physics software platformSimulates molecular interactions for biopharma and materials research
Drug discovery pipelineAdvancing internal oncology candidates through early clinical trials
Over 800 employeesMultidisciplinary scientific and software engineering workforce worldwide
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

64
OPS ScoreOperating finances
Latest quote
-3.16%$26.34
$1.98B
n/a (loss)
$269.05M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was SDGR. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Schrodinger (SDGR) do?

Schrodinger Inc (SDGR) is a U.S.-listed company in Healthcare (Health Information Services). What it does: Licenses physics-based software platforms to biopharmaceutical and industrial companies for molecular modeling. Simulates molecular interactions with physics-based software to speed up drug discovery and materials design. It is worth $1.98B on the market and sold $269.05M over the last year.

Market cap
$1.98B
P/E ratio
None (reported a loss)
Annual sales
$269.05M
Sector
Healthcare
Industry
Health Information Services
Brief updated
Nov 17, 2026

Brands and businesses behind SDGR

  • PyMOL: Molecular visualization system sold via paid licenses to structural biologists and research organizations.
  • LiveDesign: Collaborative enterprise software sold to biopharma teams for designing and tracking chemical compounds.
  • Maestro: Unified graphical interface for accessing computational chemistry applications sold on an annual subscription basis.

SDGR’s flags, in plain English

Each flag is a number from Schrodinger’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 2.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 58.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 18.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Burning Cash

Losing money, profit margin of -22%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about SDGR

How big is Schrodinger?

Schrodinger’s market cap is $1.98B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $269.05M: what customers paid the company over the last year, before any costs.

What is SDGR’s P/E ratio?

SDGR has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with SDGR?

Software licensing revenue relies heavily on biotechnology research budgets that decline during industry downturns. That is one risk on Schrodinger’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Schrodinger’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SDGR’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card